Contact Supplier

Contact Supplier

To get in touch with HAPILA GmbH, simply fill out the form below.

    Subscribe to Supplier

    Subscribe to Supplier

    .
    HAPILA brings advanced API and synthesis capabilities to Chemspec Europe 2024

    HAPILA GmbH News Releases

    Find the latest News from HAPILA GmbH

    Page 1 of 3
    HAPILA brings advanced API and synthesis capabilities to Chemspec Europe 2024
    HAPILA brings advanced API and synthesis capabilities to Chemspec Europe 2024 Learn More >
    HAPILA overcomes supply bottlenecks to synthesize anti-TB API agent BTZ-043 for clinical trials
    HAPILA overcomes supply bottlenecks to synthesize anti-TB API agent BTZ-043 for clinical trials Learn More >
    HAPILA bringing end-to-end API supply chain solutions to CPHI Barcelona
    HAPILA bringing end-to-end API supply chain solutions to CPHI Barcelona Learn More >
    HAPILA and ATHANA alliance receive funding for nanoparticle antifungal program
    HAPILA and ATHANA alliance receive funding for nanoparticle antifungal program Learn More >
    HAPILA’s co-developed anti-TB agent BTZ-043 named ‘Drug of the Year’
    HAPILA’s co-developed anti-TB agent BTZ-043 named ‘Drug of the Year’ Learn More >
    HAPILA shows advanced API development capabilities at Chemspec Europe 2023
    HAPILA shows advanced API development capabilities at Chemspec Europe 2023 Learn More >
    HAPILA finds high demand for its enhanced API development and supply capabilities at CPHI Frankfurt
    HAPILA finds high demand for its enhanced API development and supply capabilities at CPHI Frankfurt Learn More >
    HAPILA commences cGMP pilot scale manufacture of anti-TB API BTZ-043
    HAPILA commences cGMP pilot scale manufacture of anti-TB API BTZ-043 Learn More >
    HAPILA brings API manufacturing solutions to Chemspec Europe 2022
    HAPILA brings API manufacturing solutions to Chemspec Europe 2022 Learn More >
    CEP Revision extends HAPILA Estriol API retest period to 60 months
    CEP Revision extends HAPILA Estriol API retest period to 60 months Learn More >
    HAPILA extends co-operation with Transo-Pharm  to meet Estriol demand
    HAPILA extends co-operation with Transo-Pharm to meet Estriol demand Learn More >
    Authorities confirm cGMP status for HAPILA’s Estriol estrogen API manufacturing
    Authorities confirm cGMP status for HAPILA’s Estriol estrogen API manufacturing Learn More >
    Page 1 of 3